Patents Examined by Benjamin P. Blumel
  • Patent number: 11186627
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 30, 2021
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Patent number: 11179457
    Abstract: The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: November 23, 2021
    Inventors: Arun V. Iyer, Abby Rae Patterson, Joseph Gilbert Victoria, Eric Martin Vaughn, Luis Alejandro Hernandez, Jennifer L. English
  • Patent number: 11180737
    Abstract: Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: November 23, 2021
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann
  • Patent number: 11166995
    Abstract: The present invention provides an anticancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) an inhibitor of an immune checkpoint protein.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: November 9, 2021
    Assignees: OSAKA UNIVERSITY, GENOMIDEA INC.
    Inventors: Yasufumi Kaneda, Kazuma Sakura, Tomoyuki Nishikawa, Masanori Fukushima, Toshihiro Nakajima
  • Patent number: 11167025
    Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: November 9, 2021
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: George Pavlakis, Barbara Felber, James Mullins
  • Patent number: 11160859
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 2, 2021
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
  • Patent number: 11162947
    Abstract: The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 2, 2021
    Assignee: Labrador Diagnostics LLC
    Inventors: Elizabeth A. Holmes, Ian Gibbons
  • Patent number: 11147868
    Abstract: The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: October 19, 2021
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Institut National Transfusion Sanguine
    Inventors: Arnaud Chene, Benoit Gamain, Stéphane Gangnard
  • Patent number: 11141476
    Abstract: The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 12, 2021
    Assignee: CureVac AG
    Inventor: Susanne Rauch
  • Patent number: 11142567
    Abstract: Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: October 12, 2021
    Assignees: NATIONAL CHENG KUNG UNIVERSITY, DCB-USA LLC
    Inventors: Trai-Ming Yeh, Yung-Chun Chuang, Yen-Chung Lai
  • Patent number: 11135263
    Abstract: The present invention relates to MEK inhibitor, p38 inhibitor and/or NF?B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: October 5, 2021
    Assignee: Atriva Therapeutics GmbH
    Inventors: Christina Ehrhardt, Stephan Ludwig
  • Patent number: 11136379
    Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 5, 2021
    Inventors: Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
  • Patent number: 11135281
    Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 5, 2021
    Assignees: Hawaii Biotech, Inc., Infectious Disease Research Institute
    Inventors: David E. Clements, Neal Van Hoeven
  • Patent number: 11123422
    Abstract: The present invention relates to an immunogenic composition comprising two or more polypeptides. The invention also provides nucleic acid molecules and vectors encoding the polypeptides, and methods of using the compositions, nucleic acid molecules and vectors for the prevention or treatment of influenza.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: September 21, 2021
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Craig Thompson, Sunetra Gupta
  • Patent number: 11123421
    Abstract: Compositions and methods are provided for a live, attenuated influenza vaccine suitable for nasal administration. The vaccine utilizes a cold adapted influenza virus that lacks virulence factor, and includes mutations that provide replicative ability sufficient for vaccine manufacture. Vaccines so produced provide significant cross protection for non-vaccinating strains. The vaccine is safe for children under the age of 2 and adults over 49 years of age. In addition, the cold adapted, virulence factor deleted influenza virus can be adapted to provide immunity to non-influenza pathogens.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 21, 2021
    Inventors: Honglin Chen, Min Zheng, Pui Wang, Johnson Yiu-Nam Lau, Kwok Yung Yuen
  • Patent number: 11123420
    Abstract: The present invention relates to field of live attenuated recombinant tetravalent dengue vaccines and methods of producing stable compositions. Present invention specifically relates to a stable composition and methods of using such a stable composition comprising live attenuated recombinant dengue virus, stabilizer, bulking agent and optionally buffering agents, wherein the live attenuated dengue virus is generated from ? 30 and or ? 31 deleted or mutated dengue strains. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions that may comprise, inter alia, dengue virus(es). The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, dengue virus(es), which may contain these stabilizers. Other aspects of the invention are described in or are evident from the following disclosure, and are within the ambit of the invention.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: September 21, 2021
    Assignee: PANACEA BIOTEC LIMITED
    Inventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
  • Patent number: 11123423
    Abstract: Compositions and methods useful for treating and/or preventing a Zika virus infection are provided.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: September 21, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Sean P. J. Whelan, Sayantan Bose, Joseph Timpona
  • Patent number: 11117933
    Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: September 14, 2021
    Assignee: California Institute of Technology
    Inventors: Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
  • Patent number: 11111276
    Abstract: Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V 12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: September 7, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Han-Chung Wu, Chung-Tao Tang
  • Patent number: 11103453
    Abstract: The present invention relates to a rhinovaccination system of influenza vaccine, comprising a medical syringe filled with an influenza vaccine composition which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer to administer the influenza vaccine composition to nasal mucosa, which is characterized by not comprising an adjuvant.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: August 31, 2021
    Assignee: TOKO YAKUHIN KOGYO KABUSHIKI KAISHA
    Inventors: Taizou Kamishita, Takashi Miyazaki